Natalie Mount


Chief Executive Officer

Natalie is an experienced leader and innovator with a 25 year track record in drug discovery and development roles. Natalie was part of the founding management team at GammaDelta Therapeutics where she served as Chief Scientific Officer from its establishment until 2019. Previously she was part of the founding management team at the Cell and Gene Therapy Catapult as Chief Clinical Officer. Her experience also includes 16 years at Pfizer Research and Development working on different modalities across a range of therapeutic areas. Natalie has also held Independent Director positions on the Boards of biotech companies, including GenSight Biologics and Rinri Therapeutics.

Natalie holds a first class degree in Natural Sciences from University of Cambridge and a PhD from University College, London.

Mihriban Tuna


Chief Scientific Officer

Mihriban has over 15 years’ experience in biologics drug discovery and development across biotech and pharma. She joined Adaptate from F-star where she was Senior Vice President of Drug Discovery, overseeing all internal and collaborative bispecific antibody programmes from concept through to candidate selection. Previously she held key scientific roles within antibody generation and technology development at Domantis and later in Biopharm R&D at GSK.

She holds a PhD in Biochemistry from the University of Sussex and is currently studying for an executive MBA at the Judge Business School at the University of Cambridge.



Chief Business Officer

Stewart has over 20 years’ experience in business development in both biotech and large pharma and joined Adaptate in September 2020 as Chief Business Officer. He previously worked at Crescendo Biologics as Chief Business Officer and prior to that at GSK as Senior Director, Transactions in GSK’s Worldwide Business Development team, gaining significant experience in leading and closing a wide range of deals. Stewart also held the position of Vice President, Commercial Development and member of the executive management team at Pharmagene plc and as Senior Vice President, European Business Development at Evotec AG.


Stewart holds a BSc (Hons) in Biochemistry and an MBA from Warwick Business School.

Mark Uden


Chief Technology Officer

Mark has 25 years’ experience in all areas of early-stage drug development and was previously Vice President of Pharmaceutical Sciences at GammaDelta Therapeutics. Prior to this, he spent 17 years at GSK where, as Senior Director, Biopharm Development, he led a large Department accountable for early-stage GSK portfolio and platform technology deliverables ranging from lead molecule design/de-risking and process development through to phase I/II CMC technology transfer. Prior to GSK, Mark started his career at Oxford Biomedica where he helped co-invent key platform technologies still employed in commercial cell therapy products to this day.

Mark holds a PhD from Imperial College, London

Craig Taylor


Head of Business Operations

Craig’s 15-year career has provided him with broad experience in the areas of business development, finance, operations and market access, spanning nearly all segments of the life science industry.  His entrepreneurial drive has led him into numerous start-ups, including as an early employee of NanoString Technologies and as the first employee of the pioneering UK genomics company, Congenica.

Craig holds an MBA from the University of Cambridge, Judge Business School.

Craig Taylor


Head of Preclinical

Jose has 10 years’ experience in antibody discovery and preclinical development in biotech and pharma. He was previously at F-star Therapeutics where he led immune cell engager programmes from inception to pre-IND, and beyond into Phase I, spanning multiple internal and external drug candidates, publications, and patents. He also held key platform, technology, and pharmacology development roles within F-star. Before joining Adaptate, Jose also held other scientific roles within AstraZeneca and Cambridge Antibody Technology.

Jose holds a PhD in Molecular Biology from the University of Barcelona.

Talk to US

This form collects your name and email to enable us to contact you regarding your enquiry. For further information on how we protect and manage your submitted data view our privacy policy.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.